Roche Group
Grenzacherstrasse 124
Basel
CH-4070
United States
Tel: 41-61-688-8888
Fax: 41-61-688-2775
Website: http://www.roche.com/
49 articles about Roche Group
-
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
2/16/2024
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
-
Carmot Therapeutics Announces Completion of Acquisition by Roche
1/29/2024
Carmot Therapeutics Inc. today announced that its acquisition by the Roche Group (Roche) has been completed.
-
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
10/12/2023
Genentech, a member of the Roche Group, announced new clinical and real-world data for Ocrevus® demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis presented at the 9th Joint ECTRIMS-ACTRIMS Meeting.
-
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
10/11/2023
Genentech, a member of the Roche Group, announced late-breaking data from the Phase III OCARINA II study.
-
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
5/17/2023
Genentech, a member of the Roche Group, announced positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis.
-
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
11/3/2022
Genentech, a member of the Roche Group, announced that it will present new data from its industry-leading hematology portfolio at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022.
-
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
10/27/2022
Genentech, a member of the Roche Group, announced positive topline results from two global Phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo®, in macular edema due to branch and central retinal vein occlusion.
-
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
7/6/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
-
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
1/25/2022
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has granted priority review of a supplemental new drug application for the use of Evrysdi® to treat pre-symptomatic babies under two months of age with spinal muscular atrophy.
-
Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
9/7/2021
Genentech, a member of the Roche Group, announced that new oncology data will be presented at the European Society for Medical Oncology Congress, which will be held September 16-21, 2021.
-
Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
12/21/2020
Faricimab given every eight weeks and at personalized dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies
-
Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic Lymphocytic Leukemia
12/5/2020
Long-term follow-up data from the Phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta plus Rituxan
-
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
11/23/2020
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients
-
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
8/19/2020
REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection.
-
UCB enters into collaboration with Roche to develop antibody treatment for people living with Alzheimer's Disease
7/29/2020
UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment
-
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
7/14/2020
Blueprint Medicines and Genentech, a member of the Roche Group, to co-commercialize pralsetinib and equally share profits in the U.S.
-
FDA Grants Breakthrough Therapy Designation for Genentech’s Esbriet (pirfenidone) in Unclassifiable Interstitial Lung Disease
3/3/2020
The designation is based on results from a Phase II trial, which suggested Esbriet slowed disease progression in patients with uILD at 24 weeks
-
Ningbo NewBay Medical Technology Co., Ltd. Announces a License Agreement with Genentech
1/27/2020
Ningbo NewBay Medical Technology Co., Ltd. announced that it has entered into a licensing agreement with Genentech, a member of the Roche Group, under which it has been granted the exclusive global rights to further develop and commercialize GDC-0570, a small molecule Pan-PIM inhibitor that is active against multiple myeloma and prostate cancer in preclinical models.
-
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer
1/24/2020
Genentech, a member of the Roche Group, announced that the Phase III IMvigor010 study evaluating Tecentriq® as an adjuvant monotherapy treatment did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer.
-
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-free Survival in People With Unresectable Hepatocellular Carcinoma
10/21/2019
First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer